secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuBase Therapeutics, Inc. (—)
CIK:        0001173281
Form:       8-K
Filed at:   2023-06-14T23:59:59+00:00
Accession:  0001558370-23-011079
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuBase Therapeutics to effect 1-for-20 reverse stock split to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Reverse stock split at 1-for-20 effective 5:00 p.m. ET June 14, 2023; trading begins June 15 under symbol NBSE.
- Split intended to regain $1.00 minimum bid price for continued Nasdaq listing.
- Outstanding shares reduced from ~33.8 million to ~1.7 million.
- No fractional shares; cash paid in lieu based on June 13 closing price.
- Board approved ratio June 9, 2023; stockholder authorization received Sept 8, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173281/000155837023011079/0001558370-23-011079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173281/000155837023011079/nbse-20230614x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-011079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer